PETRI DISH PERSPECTIVES

Manead Khin
  • 0.0 (0)
  • LIFE SCIENCES

Burma | ChicagoScientist 🥼🧪🔬Covering biotech, pharma, and healthcare companies shaping the world 🧬🏥🌎 Stream new episodes every THURSDAY! https://linktr.ee/maneadkhin #biotech #pharma #healthcare #podcast #petridishperspectives

  1. 3D AGO

    Episode 46: Servier

    Send a text In this episode of Petri Dish Perspectives, we explore the remarkable history of Servier, France’s largest independent pharmaceutical company and one of the only major drugmakers owned by a non-profit foundation. Founded in 1954 by the physician-pharmacist Jacques Servier, the company grew from a tiny laboratory in Orléans into a global powerhouse in cardiovascular and metabolic medicine. For decades, Servier built its reputation developing treatments for hypertension and diabetes while operating outside the pressures of the public stock market. But the fortress eventually cracked. The company became embroiled in one of the most devastating medical scandals in European history surrounding the drug Mediator (benfluorex). After being marketed for decades as a diabetes treatment, the drug was linked to severe heart valve damage and pulmonary hypertension, triggering a national crisis in France and a landmark trial that reshaped pharmaceutical oversight. Yet Servier’s story does not end with scandal. In the past decade, the company has undergone a dramatic transformation, pivoting billions of euros into oncology research and acquiring cutting-edge therapies targeting rare cancers. From precision leukemia drugs like Tibsovo to the breakthrough brain-tumor therapy Voranigo, Servier is rebuilding itself as a major force in targeted cancer medicine. 🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes every Thursday! https://linktr.ee/maneadkhin #Biotech #RareDisease #BioMarin #DrugDevelopment #GeneticDiseases #Pharma #Biotechnology #LifeSciences #HealthcareInnovation #GeneTherapy #BiotechPodcast #PetriDishPerspectives Support the show © 2026 Petri Dish Perspectives LLC. All rights reserved.

    23 min

  2. MAR 5

    Episode 45: BioMarin

    Send a text Most biotech companies chase massive markets. But BioMarin Pharmaceutical built its entire strategy around something very different: ultra-rare genetic diseases affecting only small patient populations around the world. In this episode of Petri Dish Perspectives: Biotech Unleashed, we break down how BioMarin became one of the most influential rare-disease biotech companies in the industry. We explore the company’s founding vision, the scientific pathways behind its major therapies, and how its team translated academic discoveries into real treatments for patients with conditions that once had no options. We also dive into the discovery and development stories behind BioMarin’s key drugs, from enzyme replacement therapies that defined the early rare-disease model to newer innovations targeting genetic signaling pathways and gene therapy. Along the way, we examine the strategy that allowed BioMarin to build a sustainable biotech business in markets most pharma companies once ignored. If you want to understand how rare disease innovation works and why this niche has become one of the most important sectors in biotech, this episode is for you. 🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes every Thursday! https://linktr.ee/maneadkhin #Biotech #RareDisease #BioMarin #DrugDevelopment #GeneticDiseases #Pharma #Biotechnology #LifeSciences #HealthcareInnovation #GeneTherapy #BiotechPodcast #PetriDishPerspectives Support the show © 2026 Petri Dish Perspectives LLC. All rights reserved.

    24 min

  3. MAR 1

    February 2026: Biotech & Pharma NEWS Roundup

    Send a text Welcome to your essential overview of the global biotech and pharmaceutical landscape for February 2026! This month was dominated by by three massive themes: The Great IPO Thaw, the "AI Factory" Era, and Regulatory Hardball. 🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes! https://linktr.ee/maneadkhin #PetriDishPerspectives #BiotechNews #PharmaNews Support the show © 2026 Petri Dish Perspectives LLC. All rights reserved.

    11 min

  4. FEB 26

    Episode 44: BioNTech

    Send a text Before the world knew the power of mRNA vaccines, BioNTech was a relatively quiet biotech company focused on one ambitious goal: curing cancer through the immune system. Then the COVID-19 pandemic changed everything. In this episode of Petri Dish Perspectives: Biotech Unleashed, we explore how BioNTech evolved from an academic vision into one of the most important biotechnology companies of the 21st century. We break down the scientific bet on mRNA, the early years building a platform many investors didn’t fully understand, and the pivotal partnership with Pfizer that helped deliver one of the fastest vaccine developments in history. But the story doesn’t stop with COVID. We also examine the criticisms, the people behind the company’s rise, and the next frontier BioNTech is chasing — personalized cancer vaccines and the future of programmable medicine. If you want to understand how a biotech platform can reshape global health and what comes after a once-in-a-generation breakthrough, this episode is for you. 🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes every Thursday! https://linktr.ee/maneadkhin #Biotech #BioNTech #mRNA #Biotechnology #Pharma #DrugDevelopment #COVID19 #Vaccines #BiotechPodcast #LifeSciences #HealthcareInnovation #PetriDishPerspectives Support the show © 2026 Petri Dish Perspectives LLC. All rights reserved.

    25 min

  5. FEB 19

    Episode 43: ARCH Venture Partners

    Send a text In this episode of Petri Dish Perspectives, we unpack the strategy and scientific conviction behind ARCH Venture Partners, the venture firm that has quietly helped build some of the most transformative companies in modern biotechnology. From early bets on platform technologies like gene editing and mRNA to backing next-generation leaders such as Juno, Editas Medicine, Beam Therapeutics, and rising metabolic players like Metsera, ARCH has consistently invested at the frontier, long before the science was commercially proven. We explore how ARCH’s concentrated, high-conviction model differs from traditional venture capital, why it prioritizes platform biology over single assets, and how patience, scientific depth, and risk tolerance have allowed the firm to shape entire therapeutic categories. If you want to understand the invisible capital forces behind CRISPR, mRNA, cell therapy, and the obesity drug boom, this episode is for you. 🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes every Thursday! https://linktr.ee/maneadkhin #Biotech #VentureCapital #ARCHVenturePartners #Biopharma #DrugDevelopment #CRISPR #mRNA #SyntheticBiology #HealthcareInnovation #StartupEcosystem #LifeSciences #MetabolicHealth #GeneEditing #PetriDishPerspectives Support the show © 2026 Petri Dish Perspectives LLC. All rights reserved.

    24 min

  6. FEB 12

    Episode 42: Otsuka

    Send a text In this episode of Petri Dish Perspectives, we explore the fascinating evolution of Otsuka Holdings, a company that defies traditional pharmaceutical stereotypes. From its origins in Japan as a chemical and nutrition-focused business to becoming a global biopharma innovator, Otsuka has built its reputation by targeting complex and often misunderstood disease areas such as psychiatric disorders, kidney disease, and digital medicine. We unpack the scientific and business journey behind blockbuster therapies like Abilify, examine how Otsuka balanced pharmaceuticals with nutrition and consumer health, and dive into the company’s unique culture of long-term thinking and unconventional innovation. We also explore how Otsuka expanded globally, navigated patent cliffs, embraced partnerships, and positioned itself for the future through digital therapeutics and precision medicine. If you’re interested in how companies succeed by thinking differently and what Otsuka teaches us about patience, diversification, and patient-centered innovation; this is an episode you won’t want to miss. 🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes every Thursday! https://linktr.ee/maneadkhin #Biotech #Pharma #Otsuka #DrugDevelopment #HealthcareInnovation #Biopharma #LifeSciences #PharmaceuticalIndustry #MentalHealthInnovation #DigitalTherapeutics #GlobalPharma #PrecisionMedicine #PetriDishPerspectives #BiotechPodcast Support the show © 2026 Petri Dish Perspectives LLC. All rights reserved.

    23 min

  7. FEB 5

    Episode 41: Gene Therapies

    Send a text What if medicine could fix disease at its source… by rewriting the genetic code itself? In this episode of Petri Dish Perspectives, we dive into the incredible story of gene therapy, one of the most ambitious and transformative frontiers in modern medicine. From early scientific discoveries about DNA and viral delivery systems, to heartbreaking clinical setbacks that nearly shut the field down, and finally to today’s life-changing treatments for rare diseases, cancer, and genetic disorders, gene therapy represents decades of persistence, innovation, and scientific courage. We explore the researchers who refused to give up, the breakthroughs that revived the field, and the biotech companies leading today’s gene therapy revolution, including pioneers developing CRISPR editing, viral vector platforms, and personalized cellular therapies. We also break down why gene therapy is reshaping the pharmaceutical industry and what the future may hold for curing previously untreatable diseases. If you love biotech, cutting-edge science, and the stories behind medical breakthroughs, this is an episode you don’t want to miss. 🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes every Thursday! https://linktr.ee/maneadkhin #GeneTherapy #Biotech #Genetics #CRISPR #CellTherapy #RareDisease #CancerResearch #Biopharma #MedicalInnovation #PrecisionMedicine #SciencePodcast #LifeSciences #DrugDevelopment #FutureOfMedicine #PetriDishPerspectives Support the show © 2026 Petri Dish Perspectives LLC. All rights reserved.

    26 min

  8. FEB 1

    January 2026: Biotech & Pharma NEWS Roundup

    Send a text Welcome to your essential overview of the global biotech and pharmaceutical landscape for January 2026! This month was dominated by a surge in Eli Lilly's deals, partnerships, etc.  🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes! https://linktr.ee/maneadkhin #PetriDishPerspectives #BiotechNews #PharmaNews Support the show © 2026 Petri Dish Perspectives LLC. All rights reserved.

    11 min
See All (50)

About

Burma | ChicagoScientist 🥼🧪🔬Covering biotech, pharma, and healthcare companies shaping the world 🧬🏥🌎 Stream new episodes every THURSDAY! https://linktr.ee/maneadkhin #biotech #pharma #healthcare #podcast #petridishperspectives

Information

  • Creator
    Manead Khin
  • Years Active
    2025 - 2026
  • Episodes
    50
  • Rating
    Explicit
  • Copyright
    © 2026 PETRI DISH PERSPECTIVES
  • Show Website
    PETRI DISH PERSPECTIVES